CN110290803A - 膀胱癌的抗pd-l1抗体治疗 - Google Patents

膀胱癌的抗pd-l1抗体治疗 Download PDF

Info

Publication number
CN110290803A
CN110290803A CN201880011428.2A CN201880011428A CN110290803A CN 110290803 A CN110290803 A CN 110290803A CN 201880011428 A CN201880011428 A CN 201880011428A CN 110290803 A CN110290803 A CN 110290803A
Authority
CN
China
Prior art keywords
subject
antigen
bladder cancer
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880011428.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.库尔兰德
J.A.布莱克-哈斯金斯
M.扎加克
M.雷贝拉托
A.古普塔
T.何
J.沃克
X.金
S.莫里斯
R.杨诺内
L.施
M.达
Y.本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN202410133870.XA priority Critical patent/CN118001389A/zh
Publication of CN110290803A publication Critical patent/CN110290803A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880011428.2A 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗 Pending CN110290803A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410133870.XA CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410133870.XA Division CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Publications (1)

Publication Number Publication Date
CN110290803A true CN110290803A (zh) 2019-09-27

Family

ID=63169615

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880011428.2A Pending CN110290803A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗
CN202410133870.XA Pending CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410133870.XA Pending CN118001389A (zh) 2017-02-16 2018-02-16 膀胱癌的抗pd-l1抗体治疗

Country Status (12)

Country Link
US (2) US20190359715A1 (enExample)
EP (1) EP3582805A4 (enExample)
JP (2) JP2020507596A (enExample)
KR (3) KR20230145547A (enExample)
CN (2) CN110290803A (enExample)
AU (2) AU2018221822A1 (enExample)
CA (1) CA3052652A1 (enExample)
EA (1) EA201991870A1 (enExample)
IL (3) IL320916A (enExample)
MA (1) MA47509A (enExample)
SG (1) SG11201907211TA (enExample)
WO (1) WO2018152415A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP2023526400A (ja) * 2020-05-21 2023-06-21 アストラゼネカ・アクチエボラーグ 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量
WO2026003724A1 (en) * 2024-06-25 2026-01-02 Astrazeneca Ab Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328331A1 (en) * 2003-05-23 2015-11-19 Nektar Therapeutics Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
KR20170132171A (ko) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150328331A1 (en) * 2003-05-23 2015-11-19 Nektar Therapeutics Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOAQUIN BELLMUNT等: "A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now" *

Also Published As

Publication number Publication date
IL268460A (en) 2019-09-26
KR20250025517A (ko) 2025-02-21
CA3052652A1 (en) 2018-08-23
SG11201907211TA (en) 2019-09-27
IL302777A (en) 2023-07-01
JP2024038034A (ja) 2024-03-19
US20220332828A1 (en) 2022-10-20
IL320916A (en) 2025-07-01
EP3582805A4 (en) 2021-03-10
MA47509A (fr) 2019-12-25
CN118001389A (zh) 2024-05-10
EP3582805A1 (en) 2019-12-25
AU2025201227A1 (en) 2025-03-13
AU2018221822A1 (en) 2019-09-26
KR20230145547A (ko) 2023-10-17
JP2020507596A (ja) 2020-03-12
KR20190117014A (ko) 2019-10-15
EA201991870A1 (ru) 2020-02-12
WO2018152415A1 (en) 2018-08-23
US20190359715A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
EP4386005A2 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
US20160060344A1 (en) Combination therapy for pd-l1 negative tumors
JP2020512340A (ja) 無細胞ｄｎａによって測定される全身腫瘍組織量
US20240124589A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody
CN112292151B (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
WO2021160152A1 (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
JP2022517087A (ja) 癌の治療のためのｔｉｍ－３抗体および他のチェックポイント阻害剤との組み合わせ
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
KR20250116698A (ko) Dll3-발현 암의 치료 방법
CN116209466A (zh) 抗pd-1抗体在治疗鼻咽癌中的用途
WO2026052650A1 (en) Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
CN119630418A (zh) 抗GARP-TGF-β1/PD-1组合疗法
GB2535256A (en) Combination therapy for PD-L1 negative tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination